{"title":"Enhancing LDD diagnosis with YOLOv9-AID: simultaneous detection of pfirrmann grading, disc herniation, HIZ, and Schmorl's nodules.","authors":"Erling Xiang, Yongkang Zou, Jiale Chen, Jian Peng, Chunhai Huang, Feiwen Li, Xiaoping Li, Shenghua Qin, Zhiyu Li, Nanyu Li, Xu Zhou, Mingzheng Zhang","doi":"10.3389/fbioe.2025.1626299","DOIUrl":null,"url":null,"abstract":"<p><p>This study develops an intelligent diagnostic model for LDD based on a novel YOLOv9-AID detection network and evaluates the impact of multiple innovative strategies on detection performance. A total of 222 adult patients who underwent lumbar MRI for low back pain or radicular leg pain were enrolled, yielding 1110 de-identified sagittal T2-weighted images (five per case). After excluding cases with prior spinal trauma, tumors, postoperative changes, congenital malformations, or severe artefacts, 202 cases (1,010 images) were randomly divided into training, validation, and internal test sets (8:1:1), while 20 cases (100 images) formed an external dataset for generalization assessment. The YOLOv9-AID model introduces three key enhancements to the baseline YOLOv9: a SlideLoss function to rebalance training weights between high- and low-quality samples; spatial-channel collaborative attention modules (SCSA) embedded at layers 5 and 11 to strengthen lesion feature extraction; and an ExtraDW-inspired redesign of the ResNCSPELAN4 module to boost precision and reduce parameter count. In the internal test set, the model achieved an mAP50 of 82.8% and an overall detection precision of 80.3%, with Schmorl's node detection at 92.9%, Pfirrmann grading accuracy at 93.3%, and disc herniation accuracy at 73.2% (an 8.4% improvement). Recall rates increased by approximately 5% on average, with Schmorl's node recall up 15.1%, Pfirrmann recall up 1.8%, and herniation recall improvements of up to 12.3%. External validation confirmed robust generalization, and detection rates for small lesions such as high-intensity zones and Schmorl's nodes significantly outperformed conventional methods. These results demonstrate that the YOLOv9-AID network, through the integration of SlideLoss and spatial-channel attention mechanisms, substantially enhances the accuracy and robustness of LDD detection on MRI and offers a promising tool to support clinical diagnosis efficiency and consistency.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1626299"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457671/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1626299","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study develops an intelligent diagnostic model for LDD based on a novel YOLOv9-AID detection network and evaluates the impact of multiple innovative strategies on detection performance. A total of 222 adult patients who underwent lumbar MRI for low back pain or radicular leg pain were enrolled, yielding 1110 de-identified sagittal T2-weighted images (five per case). After excluding cases with prior spinal trauma, tumors, postoperative changes, congenital malformations, or severe artefacts, 202 cases (1,010 images) were randomly divided into training, validation, and internal test sets (8:1:1), while 20 cases (100 images) formed an external dataset for generalization assessment. The YOLOv9-AID model introduces three key enhancements to the baseline YOLOv9: a SlideLoss function to rebalance training weights between high- and low-quality samples; spatial-channel collaborative attention modules (SCSA) embedded at layers 5 and 11 to strengthen lesion feature extraction; and an ExtraDW-inspired redesign of the ResNCSPELAN4 module to boost precision and reduce parameter count. In the internal test set, the model achieved an mAP50 of 82.8% and an overall detection precision of 80.3%, with Schmorl's node detection at 92.9%, Pfirrmann grading accuracy at 93.3%, and disc herniation accuracy at 73.2% (an 8.4% improvement). Recall rates increased by approximately 5% on average, with Schmorl's node recall up 15.1%, Pfirrmann recall up 1.8%, and herniation recall improvements of up to 12.3%. External validation confirmed robust generalization, and detection rates for small lesions such as high-intensity zones and Schmorl's nodes significantly outperformed conventional methods. These results demonstrate that the YOLOv9-AID network, through the integration of SlideLoss and spatial-channel attention mechanisms, substantially enhances the accuracy and robustness of LDD detection on MRI and offers a promising tool to support clinical diagnosis efficiency and consistency.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.